# Development of quinoline derivatives as dual EGFR/HDAC-2 inhibitors: design, synthesis, anticancer evaluation, and molecular dynamics simulations

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41598-026-74838-0) · 2026-11-09 · Life
Page: https://themorning.science/story/development-of-quinoline-derivatives-as-dual-egfr-hdac-2-inhibitors-design-synth-13ce04332f76575e
Kind: research · Impact: low

## In brief

- A study reports the design and synthesis of quinoline derivatives as dual EGFR/HDAC-2 inhibitors.
- The work includes anticancer evaluation and molecular dynamics simulations.
- The source is a nature.com subject feed listing from 2026-11-09 with no summary provided.

## Why it matters

It describes a candidate dual-target compound class for cancer research, which matters to medicinal chemists and cancer biologists, though the feed gives no detailed results.

## Timeline

- 2026-11-09: Listed in nature.com subject feed

## Coverage

- [Development of quinoline derivatives as dual EGFR/HDAC-2 inhibitors: design, synthesis, anticancer evaluation, and molecular dynamics simulations](https://www.nature.com/articles/s41598-026-74838-0) — Biological sciences : nature.com subject feeds, 2026-11-09

Tags: quinoline, egfr, hdac-2, anticancer, molecular dynamics, drug design

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science